5-乙基-1,3-二甲基嘧啶-2,4-二酮 | 31703-08-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-乙基-1,3-二甲基嘧啶-2,4-二酮
• 英文名称: 1,3-dimethyl-5-ethyluracil
• 英文别名: 5-ethyl-1,3-dimethyl-1H-pyrimidine-2,4-dione；5-Aethyl-1,3-dimethyl-1H-pyrimidin-2,4-dion；5-ethyl-1,3-dimethylpyrimidine-2,4-dione
• CAS: 31703-08-9
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: RGFNQXKFHSVDHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为产物：
  描述：

  5-乙基-2-硫脲嘧啶 在 sodium hydroxide 、 氯乙酸 作用下， 生成 5-乙基-1,3-二甲基嘧啶-2,4-二酮
  参考文献：
  名称：

  Burckhalter; Scarborough, Journal of the American Pharmaceutical Association (1912), 1955, vol. 44, p. 545,547

  摘要：

  DOI：

文献信息

• [EN] PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES<br/>[FR] NUCLÉOSIDES PHOSPHONATES UTILES DANS LE TRAITEMENT DE MALADIES VIRALES
  申请人：UNIV CORK

  公开号：WO2015177351A1

  公开（公告）日：2015-11-26

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, and their use in medicine particular as anti-viral agents; wherein: Base is a natural or non-natural nucleobase, and the other substituents are as defined in the claims.

  本发明涉及一种式(I)的化合物，或其在药学上可接受的盐或前药，以及它们在医学上特别作为抗病毒剂的用途；其中：基团是天然或非天然的核碱基，其他取代基如权利要求中所定义。
• [EN] USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD)<br/>[FR] UTILISATION DE COMPOSITIONS MODULANT LA STRUCTURE DE LA CHROMATINE CONTRE LA MALADIE DU GREFFON CONTRE L'HÔTE (GVHD)
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016073903A1

  公开（公告）日：2016-05-12

  In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).

  在某些方面，瞬时披露涉及治疗慢性移植物抗宿主病（cGVHD）的方法。在某些实施例中，该方法包括向需要该方法的受试者施用EZH2抑制剂、Bcl6抑制剂和/或BRD4抑制剂。本公开至少部分地基于发现，增强子of zeste同源物2（EZH2）抑制剂、B细胞淋巴瘤6蛋白（Bcl6）抑制剂和/或含有bromodomain的蛋白4（BRD4）抑制剂可用于治疗慢性移植物抗宿主病（cGVHD）。
• COELENTERAZINE ANALOGUES
  申请人：PROMEGA CORPORATION

  公开号：US20170233789A1

  公开（公告）日：2017-08-17

  Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

  本发明涉及荧光素类似物，制备该类似物的方法，包含该类似物的试剂盒，以及使用该化合物进行基于荧光素酶的检测中发光的方法。
• Phosphonate nucleosides useful in the treatment of viral diseases
  申请人：University College Cork

  公开号：US10167302B2

  公开（公告）日：2019-01-01

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, and their use in medicine particular as anti-viral agents; wherein: X is selected from O and NR11; Y is selected from O, S and NR12; A is selected from —(CR1R2)n-, —(CR9R10)—, —(CR9R10)—(CR1R2)n-, —(CR1R3)—(CR2R4)—(CR1R2)n-, —CR3═CR4—(CR1R2)n- and —C≡C—(CR1R2)n-; R1 and R2 are independently selected from H, alkyl, hydroxyl, hydroxymethyl and halogen; R3 and R4 are independently selected from H and alkyl, or R3 and R4 together with the carbon atoms to which they are attached form a mono or bicyclic ring system selected from cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl and heteroaryl; R5 is selected from H, P(═O)(OH)2 and P(═O)(OH)—O—P(═O)(OH)2; R6 is selected from H and alkyl; R7 and R8 are independently selected from H, alkyl, halogen and hydroxymethyl R9 and R19 together with the carbon atoms to which they are attached form a mono or bicyclic ring system selected from cycloalkyl, cycloalkenyl, heterocycloalkyl and heterocycloalkenyl; R11 is selected from H and alkyl; R12 is selected from H and alkyl; m is 0, 1, 2 or 3; n is 1, 2 or 3; p is 0 or 1; q is 0, 1, 2 or 3; r is 0, 1, 2, 3, 4 or 5; s is 0 or 1; Base is a natural or non-natural nucleobase, and wherein each alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl and heteroaryl may be optionally substituted as described herein.

  本发明涉及式（I）化合物或其药学上可接受的盐或原药，以及它们在医药中的用途，特别是作为抗病毒剂； 其中 X 选自 O 和 NR11； Y 选自 O、S 和 NR12； A 选自-(CR1R2)n-、-(CR9R10)-、-(CR9R10)-(CR1R2)n-、-(CR1R3)-(CR2R4)-(CR1R2)n-、-CR3═CR4-(CR1R2)n-和-C≡C-(CR1R2)n-； R1 和 R2 独立选自 H、烷基、羟基、羟甲基和卤素； R3 和 R4 独立选自 H 和烷基，或 R3 和 R4 与它们所连接的碳原子一起形成选自环烷基、环烯基、杂环烷基、杂环烯基、芳基和杂芳基的单环或双环系统； R5 选自 H、P(═O)(OH)2 和 P(═O)(OH)-O-P(═O)(OH)2； R6 选自 H 和烷基； R7 和 R8 独立地选自 H、烷基、卤素和羟甲基 R9 和 R19 与它们所连接的碳原子一起形成一个单环或双环系统，该系统选自环烷基、环烯基、杂环烷基和杂环烯基； R11 选自 H 和烷基； R12 选自 H 和烷基； m 是 0、1、2 或 3； n是1、2或3 p 是 0 或 1 q 是 0、1、2 或 3； r 是 0、1、2、3、4 或 5； s 是 0 或 1； 碱基是天然或非天然核碱基，以及 其中每个烷基、环烷基、环烯基、杂环烷基、杂环烯基、芳基和杂芳基可以如本文所述被任选取代。
• Diazepane derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10308653B2

  公开（公告）日：2019-06-04

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本公开提供了式（I）化合物及其药用组合物。已发现式（I）化合物可结合溴基链和/或含溴基链的蛋白质（如溴外末端（BET）蛋白质）。还提供了这些化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基团和/或含溴基团蛋白的活性（如活性增加），治疗和/或预防受试者与溴基团或含溴基团蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、神经系统疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。